TY - JOUR
T1 - Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread
T2 - protocol for a national cross-sectional study
AU - Australian Japanese Encephalitis Virus Serosurvey Group
AU - Ella Winkler, Noni
AU - Koirala, Archana
AU - Kaur, Guddu
AU - Prasad, Shayal
AU - Hirani, Rena
AU - Baker, Jannah
AU - Hoad, Veronica
AU - Gosbell, Iain B.
AU - Irving, David O.
AU - Hueston, Linda
AU - O'Sullivan, Matthew V.N.
AU - Kok, Jen
AU - Dwyer, Dominic E.
AU - Macartney, Kristine
AU - Lambert, S.
AU - Wood, N.
AU - Snelling, T.
AU - Bakar, S.
AU - Glasgow, K.
AU - Hope, K.
AU - Baldwin, Z.
AU - Luscombe, C.
AU - Friedman, D.
AU - Marsland, M. J.
AU - Thomson, T.
AU - O’Brien, H.
AU - Williamson, D.
AU - Lim, C.
AU - Kitchener, S.
AU - Ratsch, A.
AU - Chor, J.
AU - Skyes, A.
AU - Khandaker, G.
AU - Smoll, N.
AU - Walker, J.
AU - Currie, B.
AU - Nelson, J.
AU - Hinchcliff, A.
AU - Krause, V.
AU - Worley, P.
AU - Hayward, C.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/2/7
Y1 - 2024/2/7
N2 - Method Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses. Analysis Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model. Ethics National Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. Dissemination Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
AB - Method Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses. Analysis Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model. Ethics National Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. Dissemination Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
UR - http://www.scopus.com/inward/record.url?scp=85184712598&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2023-075569
DO - 10.1136/bmjopen-2023-075569
M3 - Article
C2 - 38326269
AN - SCOPUS:85184712598
SN - 2044-6055
VL - 14
JO - BMJ Open
JF - BMJ Open
IS - 2
M1 - e075569
ER -